Focus on Janus Kinase Inhibitors in Rheumatoid Arthritis

In this video module, Gregg J. Silverman, MD, and William F. C. Rigby, MD, discuss the indications, mechanisms of action, and recent pivotal trial data regarding Janus kinase inhibitors in the management of rheumatoid arthritis.
William F. C. Rigby, MD
Gregg J. Silverman, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: August 1, 2016 Expiration: July 31, 2017

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Compare the mechanisms of action of new and emerging Janus kinase inhibitors
  • Apply results from clinical data and guideline recommendations regarding Janus kinase inhibitors in the management of rheumatoid arthritis patients now and in the future

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

William F. C. Rigby, MD

Vice Chair, Department of Medicine
Professor of Medicine, Microbiology and Immunology
Rheumatology Section
The Geisel School of Medicine at Dartmouth
Lebanon, New Hampshire

William F. C. Rigby, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Lilly, Pfizer, and Roche; fees for non-CME/CE activities from Bristol-Myers Squibb; and funds for research support from AbbVie, Bristol-Myers Squibb, Pfizer, and Roche.
Gregg J. Silverman, MD

Professor of Medicine and Pathology
NYU School of Medicine
New York, New York

Gregg J. Silverman, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Pfizer and fees for non-CME services from Bristol-Myers Squibb, Genentech.

Staff

Andrew D. Bowser, ELS, CHCP

Director, Educational Strategy and Outcomes

Andrew D. Bowser, ELS, CCMEP, has no real or apparent conflicts of interest to report.
Megan K. Murphy, PhD

Scientific Director

Megan Murphy, PhD, has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.


The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for rheumatologists, internists, primary care physicians, and other clinicians who manage patients with rheumatoid arthritis.

Goal

The goal of this activity is to improve participants’ knowledge, confidence and competence in the management of patients with rheumatoid arthritis.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.


Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 01, 2016, through July 31, 2017:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Expert commentary on real-world and trial data on treating RA after failing biologic and targeted small-molecule DMARDs, from EULAR 2020 by CCO

Eric M. Ruderman, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: August 27, 2020 Expired: August 26, 2021

Expert commentary on key studies in RA comorbidities from EULAR 2020 as reported by CCO

Paul Emery, MA, MD, FRCP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: August 24, 2020 Expired: August 23, 2021

Concise CCO expert commentary on assessment and treatment choice for patients not controlled on traditional asthma therapies

Michael E. Wechsler, MD, MMSc Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: August 24, 2020 Expired: August 23, 2021

EULAR 2020 on SELECT-CHOICE: upadacitinib vs abatacept for active rheumatoid arthritis with prior inadequate response or intolerance to bDMARDs as reported by CCO

Released: August 17, 2020
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Supported by an educational grant from
Lilly USA, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?